Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...

The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

Blue Cross Blue Shield of Texas will stop covering certain asthma infusion treatments in clinics, obliging patients to self-inject the drugs at home. The provider will cut this coverage from its plans ...

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The compan ...

Recent health news highlights a 10% rise in child TB infections in Europe, detected mammal bird flu cases, and economic ...

Current health news highlights a 10% rise in child TB infections in Europe, a new drug review by European regulators, the ...

GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...

GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...

GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...